Compare Stocks: JAZZ, AXSM, TEVA, and ONC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$143.42 +5.4%	$183.33	$123.00 ▼ $260.19	$7.52B	0.86	780,943 shs	620,365 shs
JAZZ Jazz Pharmaceuticals	$231.84 +8.1%	$231.16	$128.80 ▼ $266.38	$15.05B	0.38	929,342 shs	548,431 shs
ONC BeOne Medicines	$356.00 -1.5%	$362.88	$253.95 ▼ $388.66	$39.08B	0.61	311,359 shs	167,777 shs
TEVA Teva Pharmaceutical Industries	$42.48 +4.4%	$39.14	$20.11 ▼ $43.34	$49.45B	0.89	6.77 million shs	5.45 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-5.83%	-5.59%	-24.12%	-35.90%	+0.76%
JAZZ Jazz Pharmaceuticals	-0.71%	+4.25%	-9.01%	-18.03%	+55.80%
ONC BeOne Medicines	-2.45%	-2.59%	+0.89%	+11.84%	+16.36%
TEVA Teva Pharmaceutical Industries	-2.93%	+2.28%	+3.43%	+18.64%	+99.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$143.42 +5.4%	$183.33	$123.00 ▼ $260.19	$7.52B	0.86	780,943 shs	620,365 shs
JAZZ Jazz Pharmaceuticals	$231.84 +8.1%	$231.16	$128.80 ▼ $266.38	$15.05B	0.38	929,342 shs	548,431 shs
ONC BeOne Medicines	$356.00 -1.5%	$362.88	$253.95 ▼ $388.66	$39.08B	0.61	311,359 shs	167,777 shs
TEVA Teva Pharmaceutical Industries	$42.48 +4.4%	$39.14	$20.11 ▼ $43.34	$49.45B	0.89	6.77 million shs	5.45 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-5.83%	-5.59%	-24.12%	-35.90%	+0.76%
JAZZ Jazz Pharmaceuticals	-0.71%	+4.25%	-9.01%	-18.03%	+55.80%
ONC BeOne Medicines	-2.45%	-2.59%	+0.89%	+11.84%	+16.36%
TEVA Teva Pharmaceutical Industries	-2.93%	+2.28%	+3.43%	+18.64%	+99.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.86	Moderate Buy	$269.79	88.12% Upside
JAZZ Jazz Pharmaceuticals	2.95	Moderate Buy	$292.70	26.25% Upside
ONC BeOne Medicines	2.94	Moderate Buy	$412.26	15.80% Upside
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$46.54	9.57% Upside

Current Analyst Ratings Breakdown

Latest JAZZ, AXSM, TEVA, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/3/2026	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
11/3/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$256.00 ➝ $239.00
11/3/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$295.00 ➝ $273.00
11/3/2026	AXSM Axsome Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$275.00 ➝ $250.00
11/3/2026	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$246.00 ➝ $220.00
11/3/2026	JAZZ Jazz Pharmaceuticals	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$271.00 ➝ $275.00
11/3/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$296.00 ➝ $305.00
11/2/2026	TEVA Teva Pharmaceutical Industries	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$52.00
10/28/2026	JAZZ Jazz Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C+)
10/28/2026	JAZZ Jazz Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$276.00 ➝ $300.00
10/26/2026	AXSM Axsome Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$258.00 ➝ $238.00

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$638.50M	11.77	N/A	N/A	$1.75 per share	81.95
JAZZ Jazz Pharmaceuticals	$4.60B	3.27	$18.39 per share	12.61	$71.07 per share	3.26
ONC BeOne Medicines	$6.13B	6.38	$3.73 per share	95.53	$39.77 per share	8.95
TEVA Teva Pharmaceutical Industries	$17.26B	2.87	$3.96 per share	10.72	$6.88 per share	6.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	40.86	N/A	-24.68%	-265.55%	-28.10%	N/A
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	15.99	10.65	0.41	20.45%	33.97%	13.02%	N/A
ONC BeOne Medicines	$286.93M	$5.68	62.68	25.97	N/A	10.70%	14.23%	7.82%	11/5/2026 (Confirmed)
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	70.72	13.97	3.71	4.08%	32.64%	6.34%	11/3/2026 (Estimated)

Latest JAZZ, AXSM, TEVA, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	TEVA Teva Pharmaceutical Industries	$0.72	$0.86	+$0.14	$0.20	$4.23 billion	$4.40 billion
11/2/2026	Q3 2026	AXSM Axsome Therapeutics	-$0.6343	-$0.25	+$0.3843	-$0.25	$249.19 million	$259.69 million
11/2/2026	Q3 2026	JAZZ Jazz Pharmaceuticals	-$4.05	-$3.88	+$0.17	-$7.48	$1.21 billion	$1.24 billion
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.52	1.43	1.34
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
ONC BeOne Medicines	0.17	3.40	3.06
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
JAZZ Jazz Pharmaceuticals	89.14%
ONC BeOne Medicines	48.55%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
JAZZ Jazz Pharmaceuticals	4.10%
ONC BeOne Medicines	6.19%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	925	52.38 million	41.59 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

JAZZ, AXSM, TEVA, and ONC Headlines

Recent News About These Companies

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics

1 hour ago | zacks.com

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

1 hour ago | reuters.com

Teva Pharmaceutical Industries (NYSE:TEVA) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS

2 hours ago | marketbeat.com

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

3 hours ago | finance.yahoo.com

Teva, Samsung Bioepis Sign US Biosimilar Commercialization Deal

3 hours ago | finance.yahoo.com

Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M

3 hours ago | finance.yahoo.com

Teva Pharmaceutical Q3 profit gain beats estimates

4 hours ago | reuters.com

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

November 3 at 5:00 AM | globenewswire.com

Teva Halts TOPAS-MSA Study; Broader Emrusolmin Program Remains Under Review; Stock Up

November 2 at 5:11 PM | rttnews.com

Teva halts Phase II emrusolmin trial in multiple system atrophy after interim futility analysis

November 2 at 5:11 PM | thepharmaletter.comT

Teva Pharmaceutical Industries to Discontinue Phase 2 Study for Multiple System Atrophy Drug

November 2 at 5:11 PM | marketwatch.com

Teva discontinues phase 2 study of Emrusolmin in multiple system atrophy

November 2 at 5:11 PM | msn.com

Teva shares slide after drug trial discontinuation

November 2 at 5:11 PM | finance.yahoo.com

Sector Update: Healthcare Stocks Ease Late Afternoon

November 2 at 5:11 PM | finance.yahoo.com

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

November 2 at 5:11 PM | finance.yahoo.com

Why Is Teva Stock Trading Lower on Monday?

November 2 at 10:01 AM | benzinga.com

Teva to discontinue mid-stage neurodegenerative disorder study

November 2 at 8:18 AM | reuters.com

Teva Pharmaceutical Industries (NYSE:TEVA) Now Covered by HC Wainwright

November 2 at 8:05 AM | marketbeat.com

Teva stock: BXCL501 deal expands neuroscience pipeline

November 2 at 6:03 AM | ad-hoc-news.deA

Teva Pharmaceutical Industries (TEVA) Expected to Post Quarterly Earnings on Tuesday

November 2 at 3:28 AM | americanbankingnews.com

Teva: I Still See Upside After A Massive Rally

October 31 at 8:00 AM | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ, AXSM, TEVA, and ONC Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$143.42 +7.41 (+5.44%)

As of 11:53 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Jazz Pharmaceuticals NASDAQ:JAZZ

$231.84 +17.40 (+8.11%)

As of 11:53 AM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

BeOne Medicines NASDAQ:ONC

$356.00 -5.27 (-1.46%)

As of 11:53 AM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Teva Pharmaceutical Industries NYSE:TEVA

$42.48 +1.78 (+4.36%)

As of 11:53 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JAZZ, AXSM, TEVA, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JAZZ, AXSM, TEVA, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JAZZ, AXSM, TEVA, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ, AXSM, TEVA, and ONC Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Jazz Pharmaceuticals NASDAQ:JAZZ

BeOne Medicines NASDAQ:ONC

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JAZZ, AXSM, TEVA, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JAZZ, AXSM, TEVA, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JAZZ, AXSM, TEVA, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ, AXSM, TEVA, and ONC Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Jazz Pharmaceuticals NASDAQ:JAZZ

BeOne Medicines NASDAQ:ONC

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools